Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR)
A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors
Sponsor: Takeda
Terminated
Sponsor decision
Other terminated trials from Takeda
Other Cervical Cancer trials with similar outcome
A PHASE1 clinical study on Cervical Cancer and Cutaneous Squamous Cell Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Takeda and has accumulated 14 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
May 2025 — Sep 2025 [monthly]
Terminated PHASE1
Phase: PHASE1/PHASE2 → PHASE1
-
Sep 2024 — May 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
▶ Show 9 earlier versions
-
Apr 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2022 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
- Turnstone Biologics, Corp.
For direct contact, visit the study record on ClinicalTrials.gov .